BiotechTube
Chai Discovery

Chai Discovery

San Diego, United States· Est.
chaidiscovery.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $204.5M

Overview

Chai Discovery is a private, AI-driven biotech company engineering novel biologic therapeutics, with a core focus on antibody design. The company has developed its proprietary 'Chai-2' AI platform to move beyond simple binding prediction and towards the creation of fully developable therapeutic antibodies. With a recent $130 million Series B financing round, Chai is well-capitalized to advance its internal pipeline and platform capabilities in a competitive AI drug discovery landscape.

AntibodiesBiologics

Technology Platform

Proprietary 'Chai-2' AI platform for de novo, atomic-precision design of drug-like antibodies, integrating developability criteria beyond simple binding affinity.

Funding History

3
Total raised:$204.5M
Series A$130M
Venture$70M
Seed$4.5M

Opportunities

The company operates in the large and growing therapeutic antibody market, with an AI platform aimed at solving key industry pain points like high failure rates and long development times.
Successfully demonstrating its platform's ability to design drugs for challenging targets could lead to valuable partnerships and a robust internal pipeline.

Risk Factors

Key risks include the technical validation of its AI platform in generating clinically successful antibodies, intense competition in the AI drug discovery sector, and the execution risk of transitioning from a computational focus to integrated therapeutic development.
As a pre-revenue company, it remains dependent on milestone-driven funding.

Competitive Landscape

Chai Discovery competes in the crowded AI-driven drug discovery landscape, facing competition from other well-funded biotechs like Absci, Generate Biomedicines, and BigHat Biosciences, as well as internal efforts at large pharmaceutical companies. Its specific focus on de novo antibody design with atomic precision is a key differentiator, but it must prove superior efficacy or speed to gain market share.

More companies in AI / Machine Learning →More companies in United States →